会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Quinclidine derivatives as squalene synthase inhibitors
    • 喹喔啉衍生物作为角鲨烯合酶抑制剂
    • US5691349A
    • 1997-11-25
    • US379583
    • 1995-06-23
    • Keith Blakeney MallionGeorge Robert BrownPaul Robert Owen
    • Keith Blakeney MallionGeorge Robert BrownPaul Robert Owen
    • A61K31/435A61P3/06A61P31/04C07D453/02A61K31/46
    • C07D453/02
    • Quinuclidine derivatives of formula, and their pharmaceutically acceptable salts, in which: R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; pr R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.dbd.C--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 NH--, NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- wherein n is 0, 1 or 2; and AR is phenyl which may be optionally unsubstituted or substituted by one or more substituents such as halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, N-alkylcarbamoyl, N,N-di-alkylcarbamoyl, alkoxycarbonyl, alkythio, alkylsulphinyl, alkylsulphonyl, halogeno alkyl, alkanoylamino, alkylenedioxy, alkanoyl and oxime derivatives thereof and O-alkyl ethers of said oximes; provided that when X is selected from --OCH.sub.2 --, --NHCH.sub.2 --, and SCH.sub.2 --, R.sup.1 is not hydroxy; inhibit squalene synthase and are useful in treating diseases or medical conditions in which inhibition of squalene synthase is desirable. The use of such heterocyclic derivatives in treating conditions such as hypercholesterolemia, and atherosclerosis is referred to as well as novel compounds, processes for their preparation and pharmaceutical compositions containing them.
    • PCT No.PCT / GB93 / 01648 Sec。 371日期:1995年6月23日 102(e)日期1995年6月23日PCT提交1993年8月4日PCT公布。 公开号WO94 / 03451 日期:1994年2月17日下式的奎宁环衍生物及其药学上可接受的盐,其中:R1是氢或羟基; R2是氢; pr R1和R2连接在一起,使得CR1-CR2是双键; X选自-CH 2 CH 2 - , - CH = CH - , - C = C - , - CH 2 O - , - OCH 2 - , - CH 2 NH-,NHCH 2 - , - CH 2 CO-,-COCH 2 - , - CH 2 S(O) 和-S(O)nCH 2 - ,其中n为0,1或2; 并且AR是可任选未被取代或被一个或多个取代基如卤代,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基,二烷基氨基,N-烷基氨基甲酰基, 烷基磺酰基,烷基亚磺酰基,烷基磺酰基,卤代烷基,烷酰基氨基,亚烷基二氧基,烷酰基和肟衍生物和所述肟的O-烷基醚; 条件是当X选自-OCH 2 - ,-NHCH 2 - 和SCH 2 - 时,R 1不是羟基; 抑制角鲨烯合酶,并且可用于治疗需要抑制角鲨烯合酶的疾病或医学病症。 这些杂环衍生物在治疗诸如高胆固醇血症和动脉粥样硬化的病症中的用途也被称为新化合物,其制备方法和含有它们的药物组合物。
    • 2. 发明授权
    • Quinuclidine derivatives as squalene synthase inhibitors
    • 奎宁环衍生物作为角鲨烯合酶抑制剂
    • US5714496A
    • 1998-02-03
    • US392928
    • 1995-02-28
    • George Robert BrownKeith Blakeney MallionPaul Robert Owen WhittamoreDavid Robert Brittain
    • George Robert BrownKeith Blakeney MallionPaul Robert Owen WhittamoreDavid Robert Brittain
    • A61K31/435A61P9/10C07D453/02C07D521/00
    • C07D453/02
    • Compounds of formula (I) and their pharmaceutically acceptable salts in which R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S-- and --SCH.sub.2 --; Ar.sup.1 is a phenylene moiety; Ar.sup.2 is a heteroaryl moiety; and wherein one or both of Ar.sup.1 and Ar.sup.2 may optionally bear one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-alkylcarbamoyl, di-N,N-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, carboxyalkyl and alkanoylamino; provided that when R.sup.1 is hydroxy, X is not selected from --NHCH.sub.2 -- and --SCH.sub.2 --; are inhibitors of squalene synthase and hence useful in treating medical conditions in which a lowering of cholesterol is beneficial, such as hypercholesterolemia and atherosclerosis. Processes for preparing these derivatives, pharmaceutical compositions containing them are also described together with their use in medicine.
    • PCT No.PCT / GB93 / 01802 371日期1995年2月28日 102(e)1995年2月28日PCT PCT 1993年8月25日PCT公布。 公开号WO94 / 05660 (I)式(I)化合物及其药学上可接受的盐,其中R 1为氢或羟基; R2是氢; 或R1和R2连接在一起,使得CR1-CR2为双键; X选自-CH 2 CH 2 - , - CH = CH - , - C 3BOND C - , - CH 2 O - , - CH 2 NH - , - NHCH 2 - , - CH 2 CO - , - COCH 2 - , - CH 2 S-和-SCH 2 - Ar1是亚苯基; Ar 2是杂芳基部分; 并且其中Ar 1和Ar 2中的一个或两个可以任选地具有一个或多个独立地选自卤素,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基,二烷基氨基,N-烷基氨基甲酰基 ,二-N,N-烷基氨基甲酰基,烷氧基羰基,烷硫基,烷基亚磺酰基,烷基磺酰基,卤代烷基,羧基烷基和烷酰基氨基; 条件是当R 1为羟基时,X不选自-NHCH 2 - 和-SCH 2 - ; 是角鲨烯合酶的抑制剂,因此可用于治疗胆固醇降低有益的医学病症,例如高胆固醇血症和动脉粥样硬化。 制备这些衍生物的方法,含有它们的药物组合物也与其在药物中的用途一起被描述。
    • 3. 发明授权
    • Heterocyclic derivatives
    • 杂环衍生物
    • US5770608A
    • 1998-06-23
    • US805231
    • 1997-02-24
    • George Robert BrownKeith Blakeney MallionPeter John Harrison, deceased
    • George Robert BrownKeith Blakeney MallionPeter John Harrison, deceased
    • A61K31/435A61P9/10C07D453/02A01N43/90
    • C07D453/02A61K31/435
    • Quinuclidine compounds of the formula I: ##STR1## R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 --CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.dbd.N--, --N.dbd.CH--, --CH.sub.2 S--, --SCH.sub.2 --, wherein the sulphur atom in the latter two groups may optionally bear one or two oxygen atoms; and wherein one or both of ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkoxy, alkylamino, di-alkyl!amino, N-alkyl!carbamoyl, N,N-di-alkyl!carbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl and halogeno-alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases. Methods of using these compounds to treat such conditions, novel compounds, processes for making these compounds and pharmaceutical compositions containing them are claimed.
    • 式I的奎宁环化合物:其中R1是氢或羟基; R2是氢; 或R 1和R 2连接在一起,使得CR 1 -CR 2是双键; X选自-CH 2 CH 2 - , - CH = CH - , - C 3BOND C - , - CH 2 O - , - OCH 2 - , - CH 2 NH-, - NHCH 2 - , - CH 2 CO-,-COCH 2 - , - CH = -N = CH - , - CH 2 S - , - CH 2 - ,其中后两个基团中的硫原子可任选地具有一个或两个氧原子; 并且其中环A和环B中的一个或两个可以是任选未被取代的或独立地被一个或多个选自卤代,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,烷氧基,烷基氨基,二烷基 ]氨基,N-烷基]氨基甲酰基,N,N-二 - 烷基]氨基甲酰基,烷氧基羰基,烷硫基,烷基亚磺酰基,烷基磺酰基和卤代烷基; 是角鲨烯合酶的抑制剂,因此可用于治疗疾病或医学病症如高胆固醇血症,动脉粥样硬化和真菌性疾病。 要求使用这些化合物处理这些条件的方法,新化合物,制备这些化合物的方法和含有它们的药物组合物。
    • 4. 发明授权
    • Quinuclidine compounds useful in treating diseases
    • 奎宁环化合物可用于治疗疾病
    • US5654315A
    • 1997-08-05
    • US256123
    • 1994-06-23
    • George Robert BrownKeith Blakeney MallionPeter John Harrison, deceased
    • George Robert BrownKeith Blakeney MallionPeter John Harrison, deceased
    • A61K31/435A61P9/10C07D453/02A01N43/90
    • C07D453/02A61K31/435
    • Quinuclidine compounds of the formula I: ##STR1## R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen;or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 --CR.sup.2 is a double bond;X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.dbd.N--, --N.dbd.CH--, --CH.sub.2 S--, --SCH.sub.2 --, wherein the sulphur atom in the latter two groups may optionally bear one or two oxygen atoms; andwherein one or both of ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkoxy, alkylamino, di-alkyl]amino, N-alkyl]carbamoyl, N,N-di-alkyl]carbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl and halogeno-alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases. Methods of using these compounds to treat such conditions, novel compounds, processes for making these compounds and pharmaceutical compositions containing them are claimed.
    • PCT No.PCT / GB92 / 02333 Sec。 371日期1994年6月23日 102(e)日期1994年6月23日PCT提交1992年12月16日PCT公布。 公开号WO93 / 13096 日期:1993年7月8日式I的奎宁环化合物:其中R1是氢或羟基; R2是氢; 或R1和R2连接在一起,使得CR1-CR2为双键; X选自-CH 2 CH 2 - , - CH = CH - , - C 3BOND C - , - CH 2 O - , - OCH 2 - , - CH 2 NH-, - NHCH 2 - , - CH 2 CO-,-COCH 2 - , - CH = -N = CH - , - CH 2 S - , - CH 2 - ,其中后两个基团中的硫原子可任选地具有一个或两个氧原子; 并且其中环A和环B中的一个或两个可以是任选未被取代的或独立地被一个或多个选自卤代,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,烷氧基,烷基氨基,二烷基 ]氨基,N-烷基]氨基甲酰基,N,N-二 - 烷基]氨基甲酰基,烷氧基羰基,烷硫基,烷基亚磺酰基,烷基磺酰基和卤代烷基; 是角鲨烯合酶的抑制剂,因此可用于治疗疾病或医学病症如高胆固醇血症,动脉粥样硬化和真菌性疾病。 要求使用这些化合物处理这些条件的方法,新化合物,制备这些化合物的方法和含有它们的药物组合物。
    • 6. 发明授权
    • Biphenyl quinuclidines
    • 联苯奎宁
    • US5792777A
    • 1998-08-11
    • US81367
    • 1993-06-30
    • George Robert BrownPeter John Harrison, deceasedKeith Blakeney Mallion
    • George Robert BrownPeter John Harrison, deceasedKeith Blakeney Mallion
    • A61K31/435A61P3/06A61P9/10A61P31/04C07D20060101C07D453/02C12N9/99A61K43/40C07D453/00
    • C07D453/02
    • Biphenylylquinuclidine compounds of the formula I: ##STR1## and pharmaceutically-acceptable salts thereof; wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; and one or both ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-�(1-6C)alkyl!amino, N-�(1-6C)alkyl!carbamoyl, N,N-di-�(1-6C)alkyl!carbamoyl, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl and halogeno-(1-6C)alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases. Methods of using these compounds to treat such conditions, novel compounds, processes for making these compounds and pharmaceutical compositions containing them are claimed.
    • PCT No.PCT / GB92 / 01968 Sec。 371日期:1993年6月30日 102(e)日期1993年6月30日PCT 1992年10月27日提交了式I的联苯基奎宁环化合物:其和其药学上可接受的盐; 其中R1是氢或羟基; R2是氢; 或R1和R2连接在一起,使得CR1-CR2为双键; 并且环A和环B可以任选未被取代或独立地被一个或多个选自卤代,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,(1-6C)烷基,(1-6C)烷氧基 ,(1-6C)烷基氨基,二 - [(1-6C)烷基]氨基,N - [(1-6C)烷基]氨基甲酰基,N,N-二 - [(1-6C)烷基]氨基甲酰基,(1 -6C)烷氧基羰基,(1-6C)烷硫基,(1-6C)烷基亚磺酰基,(1-6C)烷基磺酰基和卤代 - (1-6C)烷基; 是角鲨烯合酶的抑制剂,因此可用于治疗疾病或医学病症如高胆固醇血症,动脉粥样硬化和真菌性疾病。 要求使用这些化合物处理这些条件的方法,新化合物,制备这些化合物的方法和含有它们的药物组合物。
    • 7. 发明授权
    • Heterocyclic derivatives
    • US5919793A
    • 1999-07-06
    • US537827
    • 1995-10-26
    • George Robert BrownPaul Robert Owen WhittamoreDavid Robert Brittain
    • George Robert BrownPaul Robert Owen WhittamoreDavid Robert Brittain
    • A61K31/435A61P3/06A61P9/10C07D453/02C07D435/02
    • C07D453/02
    • Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-�(1-6C)alkyl!amino, carbamoyl, (1-6C) alkylcarbamoyl, di-�(1-6C)alkyl!carbamoyl, (1-6C)alkenyl and oxime derivatives thereof and O--(1-6C)alkyl ethers of said oximes (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamimo, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di�(1-6C)alkyl!carbamoyl, amino, (1-6C)alkylamino, di-�(1-6C)alkyl!amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.